|
|
|
|
||
Re: Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDAź That is exactly the point. Each quarter they report on sales of Hepisava-B (that are actually increasing) followed by the spending of their capital to keep cancer program going. By selling the cancer program, they can use the revenue from sales to promote more sales and get the vaccine maximized to its full potential. I'd bet that if they could sell the cancer program, use that money to pay off debt, and get sales of the vaccine up, they would be profitable within a year. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1595 | Re: Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDAź | cre8profit | 0 | 6/9/2019 9:24:02 PM |